Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial (original) (raw)

Epidemiological studies indicate a high prevalence of substance use disorders (SUDs) among schizophrenia patients, with significant negative effects on their prognosis and quality of life. Conventional antipsychotics have shown limited efficacy in addressing SUDs, prompting exploration of alternative treatments. Quetiapine, due to its pharmacological similarities to clozapine, is investigated in this open-label trial for its impact on both psychiatric and substance use symptoms in patients with comorbid schizophrenia and SUDs. Results indicate that quetiapine treatment leads to significant improvements in psychiatric symptoms and a reduction in substance use, highlighting its potential as a therapeutic option for individuals with dual diagnoses.